Performance summary Business description Business review Governance Financial statements Additional information 24.
Trade and other payables 2012 2011 NonNonCurrent current Current current liabilities liabilities liabilities liabilities million million million million Trade payables 1,078 986 Interest payable 177 191 Tax and social security excluding income tax 496 408 Other payables 354 72 387 29 Accruals 875 847 Deferred income 17 13 19 12 2,997 85 2,838 41 Interest payable at 30 June 2012 included interest on non-derivative financial instruments of 168 million 2011 186 million.
Provisions Thalidomide Restructuring Other Total million million million million At 30 June 2011 168 109 138 415 Exchange differences 2 2 Acquisition of businesses 17 17 Provisions charged during the year 16 13 21 50 Provisions used during the year 16 40 34 90 Unwinding of discounts 10 1 11 At 30 June 2012 178 80 143 401 Included in current liabilities 27 43 57 127 Included in non-current liabilities 151 37 86 274 178 80 143 401 Provisions by their nature are subject to uncertainties with respect to the timing and outcomes of future events.
a A provision was established in the year ended 30 June 2005 in respect of the discounted value of the groups commitment to the UK Thalidomide Trust, and will be utilised over the period of the commitment up to 2037.
Additional provisions were made in the years ended 30 June 2012 and 30 June 2010 in respect of anticipated future payments to additional thalidomide claimants and these will be utilised up to 2030. b The group is engaged in a number of restructuring programmes, which involve the rationalisation of certain operations around the world.
Employee charges, incremental costs in respect of service contract and information systems infrastructure charges in connection with the programmes are recognised in the restructuring provision, which is expected to be substantially utilised by 30 June 2014 see note 5 a - e. c The largest item in other provisions is 46 million 2011 42 million in respect of employee deferred compensation plans which will be utilised when employees leave the company.
Notes to the consolidated financial statements 163
